Rhumbline Advisers purchased a new position in shares of Immunome, Inc. (NASDAQ:IMNM – Free Report) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 67,184 shares of the company’s stock, valued at approximately $813,000.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Clear Creek Financial Management LLC boosted its holdings in shares of Immunome by 18.2% during the second quarter. Clear Creek Financial Management LLC now owns 26,188 shares of the company’s stock worth $317,000 after acquiring an additional 4,035 shares during the period. EntryPoint Capital LLC boosted its holdings in shares of Immunome by 21,864.0% during the first quarter. EntryPoint Capital LLC now owns 5,491 shares of the company’s stock worth $136,000 after acquiring an additional 5,466 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Immunome during the second quarter worth approximately $97,000. Jump Financial LLC bought a new stake in shares of Immunome during the fourth quarter worth approximately $172,000. Finally, Sequoia Financial Advisors LLC bought a new stake in shares of Immunome during the second quarter worth approximately $206,000. Institutional investors own 44.58% of the company’s stock.
Insider Activity
In other news, CFO Max Rosett sold 14,380 shares of Immunome stock in a transaction that occurred on Thursday, September 19th. The shares were sold at an average price of $16.01, for a total value of $230,223.80. Following the completion of the sale, the chief financial officer now directly owns 47,476 shares in the company, valued at $760,090.76. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, Director Jean Jacques Bienaime acquired 7,000 shares of the stock in a transaction on Friday, August 16th. The stock was acquired at an average cost of $13.94 per share, for a total transaction of $97,580.00. Following the completion of the transaction, the director now directly owns 16,615 shares in the company, valued at $231,613.10. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Max Rosett sold 14,380 shares of the business’s stock in a transaction that occurred on Thursday, September 19th. The shares were sold at an average price of $16.01, for a total transaction of $230,223.80. Following the transaction, the chief financial officer now owns 47,476 shares of the company’s stock, valued at $760,090.76. The disclosure for this sale can be found here. 8.60% of the stock is owned by company insiders.
Analyst Ratings Changes
View Our Latest Research Report on IMNM
Immunome Trading Down 6.6 %
NASDAQ IMNM opened at $14.00 on Tuesday. Immunome, Inc. has a 1-year low of $6.80 and a 1-year high of $30.96. The company has a 50 day moving average of $14.54 and a 200-day moving average of $15.94. The company has a market cap of $839.57 million, a price-to-earnings ratio of -1.85 and a beta of 1.77.
Immunome (NASDAQ:IMNM – Get Free Report) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.11). Immunome had a negative net margin of 2,435.02% and a negative return on equity of 38.19%. The business had revenue of $2.36 million during the quarter, compared to analyst estimates of $2.62 million. On average, equities research analysts forecast that Immunome, Inc. will post -1.92 earnings per share for the current year.
Immunome Company Profile
Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.
Featured Articles
- Five stocks we like better than Immunome
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- The Average 401k Balance by Age Explained
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- Insider Trades May Not Tell You What You Think
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Want to see what other hedge funds are holding IMNM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immunome, Inc. (NASDAQ:IMNM – Free Report).
Receive News & Ratings for Immunome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunome and related companies with MarketBeat.com's FREE daily email newsletter.